Le Lézard
Classified in: Business, Covid-19 virus
Subject: ATY

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGI

NEW YORK, March 22, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Invivyd, Inc. (f/k/a Adagio Therapeutics, Inc.) ("Adagio" or the "Company") (NASDAQ: IVVD; ADGI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Adagio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On December 14, 2021, Adagio issued a press release reporting in vitro results of the Company's lead product candidate, the proposed antibody therapy ADG20, against the Omicron variant of COVID-19. The press release, which Adagio issued only a few weeks after assuring investors of ADG20's efficacy against Omicron, Adagio announced that "[t]he in vitro data generated through both authentic and pseudovirus testing of the Omicron variant show a greater than 300-fold reduction in neutralizing activity of ADG20 against Omicron." In other words, Adagio revealed that the data showed that ADG20 was 300 times less effective at neutralizing Omicron than it was against the other variants.

On this news, Adagio's stock price fell $27.00 per share, or 78.81%, to close at $7.26 per share on December 14, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Robert S. Willoughby
Pomerantz LLP
888-476-6529 ext. 7980

SOURCE Pomerantz LLP

These press releases may also interest you

at 10:21
ATS Corporation ("ATS" or the "Company"), an industry-leading automation solutions provider, today announced the closing of its previously-announced public offering of the Company's Common Shares ("Common Shares") in the United States and Canada,...

at 10:15
The "Polybutylene Terephthalate (PBT) - A Global Market Overview" report has been added to  ResearchAndMarkets.com's offering. Polybutylene Terephthalate (PBT) belongs to the group of thermoplastic polyesters. PBT is a semi-crystalline engineering...

at 10:15
The nanotechnology products market size is estimated to grow by USD 106.2 billion between 2022 and 2027 at a CAGR of 14.92%. Key factors such as the growing miniaturization of semiconductor components, increasing adoption of novel nanotechnology...

at 10:15
The meat and poultry processing equipment market size is expected to increase by USD 5,731.58 million from 2023 to 2027, registering a CAGR of over 6.03%, according to the latest research report from Technavio. The growth of the market depends...

at 10:10
The Global Medical Foods Market is Segmented by Type (Pills, Powder), by Application (Diabetic Neuropathy, ADHD, Alzheimer's Disease, Nutritional Deficiency): Global Opportunity Analysis and Industry Forecast, 2022-2029. It is published in Valuates...

at 10:03
Intersectional research is the cornerstone of understanding and tackling gender-based violence. While violence can, unfortunately, be experienced by all, certain Canadians, including Indigenous women and girls, women living in rural and remote...

News published on and distributed by: